NCT Number: NCT00960245
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Nadolol (1 x 80 mg) tablets under fasting conditions.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–40 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- No clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening.
Exclusion criteria
- Positive test results for HIV or hepatitis B or C.
- Treatment for drug or alcohol dependence.
Treatment and study plan
Corgard (1 x 80 mg) Tablets (Bristol Laboratories)
DrugPrimary outcomes
-
Bioequivalence based on AUC and Cmax
Time frame: 21 days
Sponsors and collaborators
Lead sponsor
Sandoz
Industry
Registry information
Official study title
A Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions.
Important dates
- Study start
- 1994
- Primary completion
- 1994
- Study completion
- 1994
- First posted
- Aug 17, 2009
- Registry last updated
- Mar 28, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Home Blood Pressure Telemonitoring LINKED With Community Health Workers to Improve Blood Pressure
NCT05180045
Cardiovascular Diseases, High Blood Pressure
Washington D.C., District of Columbia, United States
View Trial DetailsOptimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES)
NCT04040634
Cardiovascular Diseases, Cognition Disorders
Maceió, Alagoas, Brazil
View Trial DetailsProduce Prescription for Healthy Blood Pressure
NCT07648758
Cardiovascular Diseases, High Blood Pressure
Dallas, Texas, United States
View Trial DetailsBlood Pressure Treatment by the Corsano CardioWatch 287-2 Evaluation Study
NCT06508619
Cardiovascular Diseases, High Blood Pressure
Delft, South Holland, Netherlands
View Trial Details